Yiu-Lian / Fong

Founder/ Owner
DxRxPM Biotech Consulting, LLC.
Sr. Scientific and Corporate Strategy Adviser
MiRXES
CDO
8 Prime Biosciences

​

Professional experiences: 3
0 years of progressive R&D management and leadership roles in pharmaceutical, biotechnology, and IVD (In Vitro Diagnostics) industries. Versatile experience in all phases of vaccine and therapeutic drug (Rx) development, including discovery, preclinical, FIH, Phases 1-3 and post approval, and in all stages of IVD diagnostics (Dx) development including companion and complementary Dx and Rx co-development. Strategist for clinical/digital biomarker development.

• Chief Development Officer, 8 Prime Biosciences ( since 2025)
• Director of the Board, Senior Adviser, Shenhwa Biosciences (since 2024)
• Senior Scientific Advisor / Senior Corporate Strategy Advisor, MiRXES (since 2023)
• Founder, DxRxPM Biotech Consulting LLC (since 2024)
• Chief Scientific Officer / Chief Strategic Officer, Wuxi Life Fountain Biotech (2023-2024)
• Global Head, Clinical Biomarker & Diagnostic Strategy and Development, PH/CVM/Retina Janssen, J&J (2018- 2023)
• Global Head, R&D, Diagnostic Innovation, R&D & CLIA Lab Operation, Janssen, J&J (2015-18)
• Division Vice President, R&D, Abbott (2013-2015)
• Executive Director (2011-13), Director (2008-2011), R&D, Novartis Oncology, Novartis
• Associate Director, R&D (2006-08), Novartis Vaccines and Diagnostics, Novartis
• Associate Director (2004-2006), Sr. Scientists (2001-2003), Principal Scientist (1998-2001), Scientist (1996-1998), R&D, Chiron Pharmaceutics (1996-2001)
• Faculty position (Researcher), Johns Hopkins Univ. (1994-96)

​​
 

Speech title & Synopsis

Panel Discussion 3: MedTech

as panelist